
A transplant pharmacist looks at what azacitidine plus venetoclax’s event-free survival advantage over intensive chemotherapy means for induction selection, and why it doesn’t yet replace 7+3 or CPX-351.
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.





